Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.

Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, Pan J, Pollock KG, Palmer TJ, Cuschieri K.

Int J Cancer. 2016 Jun 15;138(12):2922-31. doi: 10.1002/ijc.30030. Epub 2016 Feb 26.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

3.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

4.

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.

Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M.

Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 10.1038/bjc.2014.479. Epub 2014 Sep 2.

5.

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.

J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. doi: 10.1093/jnci/djn510. Epub 2009 Mar 24.

6.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

7.

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.

Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M.

Br J Cancer. 2014 May 27;110(11):2804-11. doi: 10.1038/bjc.2014.198. Epub 2014 Apr 15.

8.

The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.

Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, Dillner J, Sparén P, Sundström K.

PLoS One. 2015 Jul 28;10(7):e0134185. doi: 10.1371/journal.pone.0134185. eCollection 2015.

9.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.

PMID:
24332297
10.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
11.

Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany.

Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Lüthge A, Grunwald E, Schulze-Rath R, Iftner T.

BMC Infect Dis. 2013 Mar 13;13:135. doi: 10.1186/1471-2334-13-135.

12.

HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):576-81. doi: 10.1038/bjc.2015.473. Epub 2016 Jan 22.

13.

HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Cotton S, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):582-9. doi: 10.1038/bjc.2015.474. Epub 2016 Feb 4.

14.

How does HPV vaccination status relate to risk perceptions and intention to participate in cervical screening? a survey study.

Hestbech MS, Gyrd-Hansen D, Kragstrup J, Siersma V, Brodersen J.

BMC Public Health. 2016 Aug 3;15:708. doi: 10.1186/s12889-016-3397-y.

15.

Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.

Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.

J Clin Pathol. 2015 Feb;68(2):135-40. doi: 10.1136/jclinpath-2014-202681. Epub 2014 Nov 19.

PMID:
25410654
16.

Human papillomavirus vaccination and cervical cytology in young minority women.

Brogly SB, Perkins RB, Zepf D, Longtine J, Yang S.

Sex Transm Dis. 2014 Aug;41(8):511-4. doi: 10.1097/OLQ.0000000000000162.

PMID:
25013981
17.
18.

Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.

Tshomo U, Franceschi S, Dorji D, Baussano I, Tenet V, Snijders PJ, Meijer CJ, Bleeker MC, Gheit T, Tommasino M, Clifford GM.

BMC Infect Dis. 2014 Jul 22;14:408. doi: 10.1186/1471-2334-14-408.

19.

What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.

Landy R, Windridge P, Gillman MS, Sasieni PD.

Int J Cancer. 2018 Feb 15;142(4):709-718. doi: 10.1002/ijc.31094. Epub 2017 Nov 10.

20.

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.

Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K.

BMJ Open. 2016 Feb 11;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.

Supplemental Content

Support Center